Latest

Health Elaine Chen

STAT Plus: Despite new Wegovy coverage, Medicare patients may face high drug costs and other hurdles

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Medicare and obesity drugs, FDA syringe warnings, and more

The Readout Meghana Keshavan

EU adviser says Illumina merger was not problematic

Biotech Elizabeth Cooney

STAT Plus: Drug development was once a marathon. New tools and timelines are turning it into a sprint

Opinions+ Kyle H. Sheetz and Robert M. Wachter

STAT Plus: Medical devices makers are trying to take a page from Uber’s playbook

STAT Madness Theresa Gaffney

Male birth control research wins audience over at STAT Madness event

Health Elizabeth Cooney

STAT Plus: Hospitals turn to sports performance centers to offer athletes elite care — for the right price

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Listen: Live! From the STAT Breakthrough Summit East

Health Lev Facher

Top U.S. addiction researcher calls GLP-1 data for addiction ‘very, very exciting’

Health Lev Facher

STAT Plus: Ibogaine, the psychedelic, unlikely to receive approval as opioid treatment, says top addiction researcher

Biotech Damian Garde

STAT Plus: Regeneron’s plot to ‘cure’ allergies

Biotech Annalisa Merelli

Getting CRISPR treatments to patients remains a major challenge. Could lab-developed tests help?

Biotech Andrew Joseph

STAT Plus: Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Health tech Katie Palmer and Mario Aguilar

STAT Plus: Digital tools for diabetes management did not deliver benefits that justify cost, new report finds

Biotech Megan Molteni and Eric Boodman

STAT Plus: Gene-edited pig kidney transplanted into a living patient for the first time

The Readout Damian Garde

BioNTech is having its Pfizer moment

Biotech Allison DeAngelis

STAT Plus: Prometheus team launches new startup with $400 million to tackle immune-driven disorders

Pharmalot Ed Silverman

STAT Plus: Pharma companies and their allies seek to exempt orphan drugs from state pricing limits

First Opinion Sydney Durrah

The influential adverse childhood experiences questionnaire should ask about gun violence

In the Lab Andrew Joseph

STAT Plus: U.K. health officials and researchers try to carve a path for more individualized genetic treatments

Adam's Take Adam Feuerstein

STAT Plus: A preview of Intra-Cellular Therapies’ depression drug, and sizing up the MASH opportunity

Health Lev Facher

Overdose deaths hit another record but show signs of leveling off

Politics John Wilkerson

STAT Plus: Medicare expected to negotiate obesity drug prices soon, new analysis predicts

Health Annalisa Merelli

The U.S. banned asbestos, but its health impact will still be felt for decades

The Readout Damian Garde

Novo is building a really big computer

Pharmalot Ed Silverman

STAT Plus: J&J sues former employee for allegedly taking thousands of documents to a new job at Pfizer

Biotech Allison DeAngelis

STAT Plus: Immuno-oncology startup launches with $150 million, ex-Surface, Bluebird exec as CEO

Biotech Jason Mast and Megan Molteni

STAT Plus: New gene therapy, to be priced at $4.25 million, has already transformed children’s lives